Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
3.410
+0.240 (7.57%)
At close: Aug 13, 2025, 4:00 PM
3.404
-0.006 (-0.19%)
After-hours: Aug 13, 2025, 6:31 PM EDT
Veru Inc. Employees
Veru Inc. had 210 employees as of September 30, 2024. The number of employees increased by 21 or 11.11% compared to the previous year.
Employees
210
Change (1Y)
21
Growth (1Y)
11.11%
Revenue / Employee
$80,412
Profits / Employee
-$155,764
Market Cap
49.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERU News
- 1 day ago - Veru Inc. (VERU) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 days ago - Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - GlobeNewsWire
- 7 days ago - Veru Announces Reverse Stock Split - GlobeNewsWire
- 22 days ago - Veru to Participate in the 2025 BTIG Virtual Biotech Conference - GlobeNewsWire
- 2 months ago - Veru to Participate in the Virtual BTIG Obesity Health Forum - GlobeNewsWire
- 2 months ago - Veru's Enobosarm Shows Muscle In Wegovy Combo Trial - Benzinga
- 2 months ago - Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone - GlobeNewsWire